FDA Selects Appian BPM for Process-Based Applications
Appian Enterprise Power and Ease-of-Use Aligns with FDA Strategic Vision to Transform Operations
VIENNA, Va.— October 27, 2008— Appian, an innovative global provider of business process management (BPM) technology, announced today that the U.S. Food and Drug Administration (FDA) has selected the award-winning Appian Enterprise BPM Suite as its platform of choice for the development of process-centric applications. The FDA, the scientific regulatory agency responsible for protecting and advancing the public health in the United States, chose Appian’s comprehensive BPM Suite in support of a strategic vision to transform FDA operations in response to emerging scientific, technological, and economic trends affecting its regulatory mission. This transformational vision reflects the principles of productivity and accountability embodied in the President’s Management Agenda and the e-Government initiative. The three-year contract totals $797,000.Using BPM technology, FDA expects to provide more accurate and timely data with which to make decisions that directly affect its core duties. Additionally, the time and money saved using Appian will allow a greater opportunity to enhance services to the various FDA centers.The U.S. Food and Drug Administration’s more than 10,000 scientific, technical, and support staff effect the lives of every American every day. Consumers spend nearly $1.5 trillion each year on FDA-regulated products, which represents over 20 percent of all consumer expenditures. The FDA believes that developing a process-centric approach to IT development will provide improved support in advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health. Efficiencies will be realized in better response times from IT, consistent development practices and artifacts produced from projects, and a reduced effort to manage total contractor teams. By providing standard reference architecture, development practices, tools, and examples through reference implementation, the FDA will be able to transform its IT practices into a holistic approach that better-serves the enterprise and the public.
“BPM is fundamentally changing the way government agencies operate,” said Matthew Calkins, President and CEO of Appian. “Viewing application development as an agency-wide effort instead of each individual center managing their own practices will improve the coordination and orchestration of how IT supports the FDA’s mission.”
About the U.S. Food and Drug Administration (FDA)
The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.
Appian delivers an enterprise platform for digital transformation that enables organizations to revolutionize their customer experience, optimize their business operations, and master global risk and compliance. Powered by industry leading Business Process Management (BPM) and Case Management capabilities, Appian’s low-code approach radically accelerates the time it takes to build and deploy powerful, modern applications, on-premises or in the cloud. For more information, visit www.appian.com.